Drug Companies Should Sue Competitors For Off-Label Promotion
Executive Summary
Drug companies should challenge off-label promotion by competitors in the same way they defend their patents against infringement, U.S. Attorney Michael Loucks said
You may also be interested in...
TAP Lupron Sales Execs Plead Not Guilty; Pre-Trial Work Begins
The criminal case against one current and five former TAP sales executives is expected to complete the pre-trial phase by spring 2002.
FDA Has "Substantial Interest" In Reviewing Off-Label Uses, Judge Rules
FDA has a "substantial interest" in adding off-label uses of previously approved drugs to product labeling, D.C. federal court Judge Royce Lamberth ruled July 30 in the first amendment case brought against FDA by the Washington Legal Foundation.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011